Work

A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps8554

Authors: Maria-Victoria Mateos, Philippe Moreau, Meletios A. Dimopoulos, Wan-Jen Hong, Scott Cooper, Yao Yu, Muhammad Jalaluddin, Jeremy A. Ross, Sudeep Karve, Sheryl Coppola, Paulo Cesar Maciag, Orlando Bueno, Emma Louise Arriola, Shaji Kumar

Institutions: Universidad de Salamanca, Centre Hospitalier Universitaire de Nantes, National and Kapodistrian University of Athens, Genentech, AbbVie (United Kingdom), AbbVie (United States), Mayo Clinic

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: AbbVie

OpenAlex ID: W3032678307

Cites:

Cited by: 17

Related to: 10